Cargando…

Safety of aromatase inhibitors in the adjuvant setting

The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer. Although AIs have demonstrated superior efficacy and better overall safety compared with tamoxifen in randomized c...

Descripción completa

Detalles Bibliográficos
Autor principal: Perez, Edith A.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001222/
https://www.ncbi.nlm.nih.gov/pubmed/17912638
http://dx.doi.org/10.1007/s10549-007-9704-7